WO2004094345A3 - Protected monomers - Google Patents
Protected monomers Download PDFInfo
- Publication number
- WO2004094345A3 WO2004094345A3 PCT/US2004/011822 US2004011822W WO2004094345A3 WO 2004094345 A3 WO2004094345 A3 WO 2004094345A3 US 2004011822 W US2004011822 W US 2004011822W WO 2004094345 A3 WO2004094345 A3 WO 2004094345A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protected monomers
- monomers
- protected
- synthesis
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/22—Pteridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
Abstract
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004232964A AU2004232964B2 (en) | 2003-04-17 | 2004-04-16 | Protected monomers |
EP04759940A EP1625138A4 (en) | 2003-04-17 | 2004-04-16 | Protected monomers |
US10/553,659 US20070179100A1 (en) | 2003-04-09 | 2004-04-16 | Protected monomers |
JP2006513075A JP4991288B2 (en) | 2003-04-17 | 2004-04-16 | A double-stranded iRNA agent and a method of modulating the stability of a pair of double-stranded iRNA agents. |
CA002522349A CA2522349A1 (en) | 2003-04-17 | 2004-04-16 | Protected monomers |
US10/916,185 US7745608B2 (en) | 2003-04-17 | 2004-08-10 | Modified iRNA agents |
US10/936,115 US20050119214A1 (en) | 2003-04-17 | 2004-09-07 | Nuclease resistant double-stranded ribonucleic acid |
US10/946,873 US20050164235A1 (en) | 2003-04-17 | 2004-09-21 | Modified iRNA agents |
US10/985,426 US7723509B2 (en) | 2003-04-17 | 2004-11-09 | IRNA agents with biocleavable tethers |
US11/833,934 US7851615B2 (en) | 2003-04-17 | 2007-08-03 | Lipophilic conjugated iRNA agents |
US12/510,050 US8017762B2 (en) | 2003-04-17 | 2009-07-27 | Modified iRNA agents |
US12/619,382 US8344125B2 (en) | 2003-04-17 | 2009-11-16 | Modified iRNA agents |
US12/714,298 US8507661B2 (en) | 2003-04-17 | 2010-02-26 | Modified iRNA agents |
US12/724,267 US8426377B2 (en) | 2003-04-17 | 2010-03-15 | iRNA agents with biocleavable tethers |
US15/260,803 US10119138B2 (en) | 2003-04-17 | 2016-09-09 | iRNA agents with biocleavable tethers |
US15/906,908 US10676740B2 (en) | 2003-04-17 | 2018-02-27 | Modified iRNA agents |
US16/042,633 US11015194B2 (en) | 2003-04-17 | 2018-07-23 | iRNA agents with biocleavable tethers |
US17/243,503 US20210254065A1 (en) | 2003-04-17 | 2021-04-28 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS |
US17/697,685 US20220403377A1 (en) | 2003-04-17 | 2022-03-17 | MODIFIED iRNA AGENTS |
Applications Claiming Priority (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46377203P | 2003-04-17 | 2003-04-17 | |
US60/463,772 | 2003-04-17 | ||
US46580203P | 2003-04-25 | 2003-04-25 | |
US46566503P | 2003-04-25 | 2003-04-25 | |
US60/465,665 | 2003-04-25 | ||
US60/465,802 | 2003-04-25 | ||
US46961203P | 2003-05-09 | 2003-05-09 | |
US60/469,612 | 2003-05-09 | ||
US49398603P | 2003-08-08 | 2003-08-08 | |
US60/493,986 | 2003-08-08 | ||
US49459703P | 2003-08-11 | 2003-08-11 | |
US60/494,597 | 2003-08-11 | ||
US50634103P | 2003-09-26 | 2003-09-26 | |
US60/506,341 | 2003-09-26 | ||
US51024603P | 2003-10-09 | 2003-10-09 | |
US60/510,246 | 2003-10-09 | ||
US51031803P | 2003-10-10 | 2003-10-10 | |
US60/510,318 | 2003-10-10 | ||
US51845303P | 2003-11-07 | 2003-11-07 | |
US60/518,453 | 2003-11-07 | ||
USPCT/US04/07070 | 2004-03-08 | ||
PCT/US2004/007070 WO2004080406A2 (en) | 2003-03-07 | 2004-03-08 | Therapeutic compositions |
PCT/US2004/010586 WO2004090108A2 (en) | 2003-04-03 | 2004-04-05 | Irna conjugates |
USPCT/US04/010586 | 2004-04-05 | ||
PCT/US2004/011255 WO2004091515A2 (en) | 2003-04-09 | 2004-04-09 | iRNA CONJUGATES |
USPCT/US04/11255 | 2004-04-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004094345A2 WO2004094345A2 (en) | 2004-11-04 |
WO2004094345A3 true WO2004094345A3 (en) | 2005-11-10 |
WO2004094345A8 WO2004094345A8 (en) | 2016-06-30 |
Family
ID=35519758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/011822 WO2004094345A2 (en) | 2003-04-09 | 2004-04-16 | Protected monomers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1625138A4 (en) |
JP (1) | JP4991288B2 (en) |
AU (1) | AU2004232964B2 (en) |
CA (1) | CA2522349A1 (en) |
WO (1) | WO2004094345A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
EP2982754A1 (en) | 2004-09-24 | 2016-02-10 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of apob and uses thereof |
US7790878B2 (en) | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
US7592322B2 (en) | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
JP2008521401A (en) | 2004-11-24 | 2008-06-26 | アルナイラム ファーマシューティカルズ インコーポレイテッド | RNAi regulation of BCR-ABL fusion gene and method of use thereof |
WO2006066158A2 (en) | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
CN102600480B (en) | 2005-01-07 | 2015-07-22 | 阿尔尼拉姆医药品有限公司 | RNAI modulation of RSV and therapeutic uses thereof |
WO2007002718A2 (en) | 2005-06-27 | 2007-01-04 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of hif-1 and theraputic uses thereof |
EP2230305A1 (en) | 2005-07-21 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Rnai modulation of the rho-a gene and uses thereof |
EP1951737A4 (en) | 2005-11-01 | 2009-07-01 | Alnylam Pharmaceuticals Inc | Rnai inhibition of influenza virus replication |
WO2007109097A2 (en) | 2006-03-16 | 2007-09-27 | Alnylam Pharmaceuticals, Inc. | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
NZ571568A (en) | 2006-03-31 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene |
KR101141544B1 (en) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | Multi-conjugate of siRNA and preparing method thereof |
WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
WO2016205410A2 (en) | 2015-06-15 | 2016-12-22 | Mpeg La, Llc | Defined multi-conjugate oligonucleotides |
MX2018002090A (en) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof. |
SG11201906728TA (en) | 2017-02-06 | 2019-08-27 | Mpeg La Llc | Multimeric oligonucleotides having decreased kidney clearance |
KR20240017813A (en) | 2021-05-10 | 2024-02-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | Pharmaceutical composition for treating neurological diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041809A1 (en) * | 1995-06-09 | 1996-12-27 | The Regents Of The University Of Colorado | Novel protecting groups and use thereof in an improved process for oligonucleotide synthesis |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795866A (en) | 1972-02-29 | 1973-08-23 | Basf Ag | PROCESS FOR THE PREPARATION OF SOLID CHOLINE CHLORIDE FREE FLOW |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
FR2594693B1 (en) | 1986-02-24 | 1990-01-05 | Farah Nabil | NOVEL PROCESSES FOR THE PREPARATION FROM DRY EMULSIONS OF SOLID ORAL FORMS WITH MODIFIED AND DELAYED RELEASE OF THEIR ACTIVE INGREDIENTS |
SE8701479L (en) | 1987-04-09 | 1988-10-10 | Carbomatrix Ab | METHOD FOR CONTAINING BIOLOGICALLY EFFECTIVE PREPARATIONS AND USE THEREOF |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
JPH0436233A (en) | 1990-05-29 | 1992-02-06 | Biomaterial Universe Kk | Sustained release preparation containing physiologically active substance and decomposable and absorbable in living body |
EP0547142A1 (en) * | 1990-08-28 | 1993-06-23 | Epoch Pharmaceuticals, Inc. | Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304620D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Compounds |
JPH07101882A (en) | 1993-09-30 | 1995-04-18 | Sanei Gen F F I Inc | Preparation containing water-soluble hemicellulose |
JPH07101881A (en) | 1993-09-30 | 1995-04-18 | Sanei Gen F F I Inc | Preparation containing water-soluble hemicellulose |
JPH07101884A (en) | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | Prpearation containing water-soluble hemicellulose |
JP3342550B2 (en) | 1993-10-01 | 2002-11-11 | 三栄源エフ・エフ・アイ株式会社 | Formulations containing water-soluble hemicellulose |
US5652359A (en) * | 1993-12-02 | 1997-07-29 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing n-methyl thiolated bases having antiviral activity |
JPH07242568A (en) | 1994-03-04 | 1995-09-19 | Eisai Co Ltd | Pharmaceutical preparation for masking bitterness |
US5691316A (en) | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
CA2220950A1 (en) | 1995-05-26 | 1996-11-28 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
TR200401292T3 (en) | 2000-12-01 | 2004-07-21 | Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften | the rnaágirişimineáyoláaçanáküçükárnaámolekül |
TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
-
2004
- 2004-04-16 EP EP04759940A patent/EP1625138A4/en not_active Withdrawn
- 2004-04-16 CA CA002522349A patent/CA2522349A1/en not_active Abandoned
- 2004-04-16 JP JP2006513075A patent/JP4991288B2/en not_active Expired - Lifetime
- 2004-04-16 AU AU2004232964A patent/AU2004232964B2/en not_active Expired
- 2004-04-16 WO PCT/US2004/011822 patent/WO2004094345A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041809A1 (en) * | 1995-06-09 | 1996-12-27 | The Regents Of The University Of Colorado | Novel protecting groups and use thereof in an improved process for oligonucleotide synthesis |
Non-Patent Citations (2)
Title |
---|
ELBASHIR S.M. ET AL: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, vol. 20, no. 23, 3 December 2001 (2001-12-03), pages 6877 - 6888, XP002225998 * |
See also references of EP1625138A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
Also Published As
Publication number | Publication date |
---|---|
CA2522349A1 (en) | 2004-11-04 |
AU2004232964B2 (en) | 2011-09-22 |
JP4991288B2 (en) | 2012-08-01 |
AU2004232964A1 (en) | 2004-11-04 |
EP1625138A4 (en) | 2010-06-23 |
EP1625138A2 (en) | 2006-02-15 |
WO2004094345A8 (en) | 2016-06-30 |
WO2004094345A2 (en) | 2004-11-04 |
JP2007525453A (en) | 2007-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004094345A3 (en) | Protected monomers | |
WO2008083248A3 (en) | Cyclopamine analogs | |
WO2004092123A3 (en) | Inhibitors of fungal invasion | |
EP1620544A4 (en) | MODIFIED iRNA AGENTS | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
EP1587535A4 (en) | Title of the invention n-cyclohexylaminocarbonyl benzenesulfonamide derivatives | |
MXPA05013553A (en) | Pyrrolodihydroisoquinolines as pde10 inhibitors. | |
GB0326286D0 (en) | Initiator systems for polymerisable compositions | |
LT1778711T (en) | Synthesis of protected 3`-amino nucleoside monomers | |
HK1096661A1 (en) | An intermediate for the industrial synthesis of substituted thiophenecarboxylate | |
WO2007098124A3 (en) | Processes for the convergent synthesis of calicheamicin derivatives | |
WO2006075139A3 (en) | Novel process for the preparation of substituted indoles | |
AU2003273083A1 (en) | Compositions for the improvement of obesity | |
WO2006135883A8 (en) | Assortment of antiperspirants having two or more product performance characteristics | |
WO2004075021A3 (en) | Molecular modeling methods | |
WO2007070563A3 (en) | Stable solid forms of enterostatin | |
WO2004048380A8 (en) | Process for the synthesis of ganciclovir | |
GB0327323D0 (en) | Novel pharmaceuticals | |
AU2003206367A1 (en) | Technical field of the invention | |
WO2005060981A3 (en) | Pharmaceutical compositions | |
IL189547A0 (en) | Synthesis of 1??-fluoro-25-hydroxy | |
WO2004026892A3 (en) | Fragmentation of dna | |
WO2003097593A3 (en) | Protease inhibitors | |
WO2004021997A8 (en) | Inhibitors of fungal invasion | |
WO2004039352A3 (en) | Amorphous form of losartan potassium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2522349 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006513075 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004232964 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2004759940 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004759940 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004232964 Country of ref document: AU Date of ref document: 20040416 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004232964 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004759940 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10553659 Country of ref document: US Ref document number: 2007179100 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10553659 Country of ref document: US |